 |
|
|
|
|
 |
Last Updated: Nov 1, 2009 - 11:48:48 PM |
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration Phase
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin(TM) Anti-Viral for the treatment of chronic hepatitis C virus infection (HCV).
Jan 18, 2006 - 6:00:37 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin effective in controlling Pancreatic Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced preclinical results showing that 3G4, the mouse equivalent of Tarvacin(TM) Anti-Cancer, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy when combined with the standard-of-care chemotherapy gemcitabine.
Jan 11, 2006 - 7:20:37 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Peregrine Pharmaceuticals Evaluating Therapeutic Opportunities for Tarvacin
Oct 25, 2005 - 5:10:38 AM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) starts with Phase I study against Hepatitis C Virus
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), announced today the initiation of a phase I anti-viral study of Tarvacin(TM), the Company's first Anti-Phospholipid Therapy candidate. The phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy.
Aug 8, 2005 - 5:39:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
New data support broad anti-viral potential of Tarvacin(TM)
The data presented at BIO 2005 showed that Tarvacin(TM) binds to enveloped virus particles representing 6 different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin(TM) provided significant protection against Cytomegalovirus (CMV) and Pichinde virus (an in vivo Lassa fever model) infections.
Jul 31, 2005 - 11:59:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) also useful in imaging solid tumors
Peregrine Pharmaceuticals, Inc reported that data was presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California showing the potential use of Tarvacin(TM), its lead Anti-Phospholipid Therapy agent, for imaging solid tumors.
Jul 31, 2005 - 11:12:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Tarvacin
Tarvacin(TM) to be evaluated for the treatment of Lassa fever
Peregrine Pharmaceuticals Inc. has announced that it has signed a Cooperative Research and Development Agreement (CRADA) for Material Transfer with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of Tarvacin(TM) to treat hemorrhagic diseases resulting from Ebola and Marburg viral infections.
Jul 31, 2005 - 11:01:38 PM
|
<< prev
next >>
|
|
|
|
